Hits, but mostly misses for Roche’s 4 late-stage trials of GI drug hopeful etrolizumab

Roche’s batch of phase 3 tests of its experimental GI drug etrolizumab has not gone to plan, with “mixed results” highlighting a murky picture for its ulcerative colitis (UC) program.